136 related articles for article (PubMed ID: 3349566)
1. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination.
Satoh M; Naganuma A; Imura N
Cancer Chemother Pharmacol; 1988; 21(2):176-8. PubMed ID: 3349566
[TBL] [Abstract][Full Text] [Related]
2. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice.
Naganuma A; Satoh M; Imura N
Jpn J Cancer Res; 1988 Mar; 79(3):406-11. PubMed ID: 3131288
[TBL] [Abstract][Full Text] [Related]
3. Induction of renal metallothionein allows increasing dose of an extensively used antitumor drug, cis-diamminedichloroplatinum.
Imura N; Naganuma A; Satoh M; Koyama Y
Experientia Suppl; 1987; 52():655-60. PubMed ID: 2959559
[TBL] [Abstract][Full Text] [Related]
4. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.
Naganuma A; Satoh M; Imura N
Cancer Res; 1987 Feb; 47(4):983-7. PubMed ID: 3802104
[TBL] [Abstract][Full Text] [Related]
5. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
Kondo Y; Himeno S; Satoh M; Naganuma A; Nishimura T; Imura N
Cancer Chemother Pharmacol; 2004 Jan; 53(1):33-8. PubMed ID: 14530870
[TBL] [Abstract][Full Text] [Related]
6. Effect of preinduction of metallothionein synthesis on clastogenicity of anticancer drugs in mice.
Nakagawa I; Nishi E; Naganuma A; Imura N
Mutat Res; 1995 Sep; 348(1):37-43. PubMed ID: 7565913
[TBL] [Abstract][Full Text] [Related]
7. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice.
Satoh M; Naganuma A; Imura N
Life Sci; 2000 Jun; 67(6):627-34. PubMed ID: 12659168
[TBL] [Abstract][Full Text] [Related]
8. Protective role of metallothionein in renal toxicity of cisplatinum.
Satoh M; Aoki Y; Tohyama C
Cancer Chemother Pharmacol; 1997; 40(4):358-62. PubMed ID: 9225956
[TBL] [Abstract][Full Text] [Related]
9. Prevention of adverse effects of gamma-ray irradiation after metallothionein induction by bismuth subnitrate in mice.
Satoh M; Miura N; Naganuma A; Matsuzaki N; Kawamura E; Imura N
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1727-31. PubMed ID: 2632256
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor.
Kondo Y; Satoh M; Imura N; Akimoto M
Anticancer Res; 1992; 12(6B):2303-7. PubMed ID: 1295477
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract.
Khandekar JD; Elson PJ; DeWys WD; Slayton RE; Harris DT
J Clin Oncol; 1985 Apr; 3(4):539-45. PubMed ID: 3884746
[TBL] [Abstract][Full Text] [Related]
12. High-dose cis-platinum in combination with adriamycin in the treatment of ovarian carcinoma.
Choo YC; Wong LC; Ma HK
Eur J Gynaecol Oncol; 1984; 5(3):203-6. PubMed ID: 6376128
[TBL] [Abstract][Full Text] [Related]
13. [Role of metallothionein in cancer chemotherapy].
Naganuma A; Imura N
Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
[TBL] [Abstract][Full Text] [Related]
14. Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice.
Satoh M; Naganuma A; Imura N
Cancer Chemother Pharmacol; 1992; 30(6):439-43. PubMed ID: 1394800
[TBL] [Abstract][Full Text] [Related]
15. Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum in mice.
Satoh M; Naganuma A; Imura N
J Pharmacobiodyn; 1989 Apr; 12(4):246-53. PubMed ID: 2795434
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate].
Hamada T; Nishiwaki Y; Kodama T; Hayashibe A; Nukariya N; Sasaki H; Morikawa T; Hirosawa T; Matsuyama T
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3587-93. PubMed ID: 2554815
[TBL] [Abstract][Full Text] [Related]
17. Depression of toxic effects of anticancer agents by selenium or pretreatment with metallothionein inducers.
Imura N; Naganuma A; Satoh M; Koyama Y
J UOEH; 1987 Mar; 9 Suppl():223-9. PubMed ID: 3602747
[No Abstract] [Full Text] [Related]
18. Protective effect of metallothionein inducing metals on lethal toxicity of cis-diamminedichloroplatinum in mice.
Naganuma A; Satoh M; Koyama Y; Imura N
Toxicol Lett; 1985; 24(2-3):203-7. PubMed ID: 4039080
[TBL] [Abstract][Full Text] [Related]
19. [Metallothionein as a resistance factor for antitumor drugs].
Imura N; Naganuma A; Satoh M
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):599-604. PubMed ID: 2705789
[TBL] [Abstract][Full Text] [Related]
20. Selenium efficiently depressed toxic side effect of cis-diamminedichloroplatinum.
Naganuma A; Satoh M; Yokoyama M; Imura N
Res Commun Chem Pathol Pharmacol; 1983 Oct; 42(1):127-34. PubMed ID: 6685904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
